Connoya introduced CMG901, novel drug for the treatment of Claudin 18.2-positive advanced gastric cancer. This new drug is indicated after first-line or treatment failure or intolerance.
CMG901 previously granted orphan drug designation and fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory gastric cancer and gastroesophageal junction adenocarcinoma. Hence, CMG901 serves as the better treatment of Claudin 18.2-positive advanced gastric cancer.
Gastric cancer is a malignant tumor of epithelial origin originating from stomach. Globally, more than 1 million new gastric cancer cases arise every year causing nearly 769,000 deaths.
During first diagnosis, due to the atypical early symptoms of gastric cancer, 80% to 90% of gastric cancer patients are in the advanced stage, losing the chance of radical surgery.
Since gastric cancer is highly heterogeneous, the targeted therapy drugs are scarce. Currently, there are no targeted drugs approved for first-line treatment of HER2 in market.
